Impel Pharmaceuticals Inc   (IMPL)
Other Ticker:  
Price: $0.0400 $-0.02 -27.273%
Day's High: $0.05 Week Perf: -89.36 %
Day's Low: $ 0.02 30 Day Perf: -87.1 %
Volume (M): 720 52 Wk High: $ 2.87
Volume (M$): $ 29 52 Wk Avg: $0.98
Open: $0.05 52 Wk Low: $0.02

 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 24
 Employees -
 Revenues (TTM) (Millions $) 8
 Net Income (TTM) (Millions $) -74
 Cash Flow (TTM) (Millions $) -75
 Capital Exp. (TTM) (Millions $) 3

Impel Pharmaceuticals Inc
Impel Pharmaceuticals Inc is a pharmaceutical company that focuses on developing innovative drug delivery systems for the treatment of various neurological disorders. They aim to deliver drugs directly to the brain for more targeted and effective treatment.

Impel Pharmaceuticals utilizes their proprietary Precision Olfactory Delivery, or POD, technology to administer therapies via the nasal cavity. This approach allows for rapid and efficient drug absorption, bypassing the blood-brain barrier for enhanced efficacy.

The company has a particular focus on developing treatments for migraine and other headaches, as well as other neurological conditions such as Parkinson's disease and schizophrenia. They have several drug candidates in their pipeline, and their technology has shown promising results in clinical trials.

Impel Pharmaceuticals strives to revolutionize neurological drug delivery and improve patient outcomes by providing more precise and convenient treatment options.

   Company Address: 201 Elliott Avenue West Seattle 98119 WA
   Company Phone Number: 568-1466   Stock Exchange / Ticker: NASDAQ IMPL
   IMPL is expected to report next financial results on March 26, 2024.


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Impel Pharmaceuticals Inc

Impel Pharmaceuticals Inc Delivers Remarkable Revenue Growth Despite Third Quarter Losses Impel Pharmaceuticals Inc Reports Positive Financial Results for Q3 2023

Impel Pharmaceuticals Inc: Bullish Outlook Despite Recent Losses
For the financial time-frame closing September 30, 2023, Impel Pharmaceuticals Inc reported losses of $-0.58 per share, compared to $-1.31 per share in the same period a year ago. However, it is important to note that this represents a significant improvement from the prior quarter, where the losses stood at $-0.31 per share.
Although the company faced losses, Impel Pharmaceuticals Inc managed to achieve substantial revenue growth. The revenue increased by a remarkable 55.516% to $4.79 million from $3.08 million in the corresponding quarter a year prior. It is also worth mentioning that the sequential revenue saw a small decline of -24.686% from $6.36 million, which can be attributed to normal business fluctuations.
This positive revenue growth sets Impel Pharmaceuticals Inc apart from its contemporaries in the Major Pharmaceutical Preparations sector. While most companies in this sector experienced a decline in revenues during the same period, Impel Pharmaceuticals Inc witnessed a surge. This is a testament to the company's ability to withstand the sector's momentum and generate strong sales.
Furthermore, Impel Pharmaceuticals Inc reported a net loss of $-13.814 million for the financial time-frame closing September 30, 2023. This marks a significant improvement compared to the deficit of $-31.097 million reported in the corresponding quarter a year ago. This indicates that the company is taking measures to reduce its losses and improve its financial performance.

Impel Pharmaceuticals Inc

Impel Pharmaceuticals Inc Reports Record-Breaking Revenue Surge in Q2 2023 Earnings Season, Signaling Strong Market Potential

Impel Pharmaceuticals Inc has experienced a significant decline in its shares over the last five trading days, resulting in a year-to-date performance drop of 90.19%. However, recent financial results reveal positive indicators, including a reduced loss per share and substantial revenue growth. Examining the implications of these results, it is worthwhile to consider how they may impact the company's future prospects.
1. Strong Revenue Growth:
In the second quarter of 2023, Impel Pharmaceuticals Inc witnessed a remarkable revenue surge of 127.042%, reaching $6.36 million compared to $2.80 million in the same quarter the previous year. Additionally, sequentially, revenue increased by 45.563% from $4.37 million. This impressive growth hints at expanding product demand and positive market reception. Furthermore, the increase in revenue indicates strong potential for future profit generation.

Impel Pharmaceuticals Inc

Impel Pharmaceuticals Inc. Shows Remarkable Growth and Revenue Surge in First Quarter of 2023

Impel Pharmaceuticals Inc announced a very solid revenue rise of 148.55% year on year to $4.37 million in the January to March 31, 2023 span, which is good news for the company. Although it was noted that there was a loss per share at $-1.27, which represented an increase in loss in proportion to the preceding reporting season, this is a common occurrence and fluctuations can be expected in the financial sector. The previous reporting season had a loss of $-0.98 per share, however, revenue turned positive from $-7.31 million, which is a positive sign regardless of the loss per share.
The financial period ending March 31, 2023, saw Impel Pharmaceuticals Inc realizing a net loss of $-30.067 million, which is larger than the $-26.970 million recorded the previous year. This may be a cause for concern for investors, but it's important to note that the company is still making a profit, albeit a smaller one, and is still showing a strong trajectory towards growth and financial stability.


Impel Pharmaceuticals Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com